Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Five Prime Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2001 · IPO 2013 Unicorn

Innovative Protein Therapeutics

Valuation
$1.90B
Market cap · 2026
Revenue
$12M
Latest reported FY

Investors

7 investors on Five Prime Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage
Advanced Technology Ventures
HealthCap
Domain Associates
Diamond Capital Company
Wellcome Trust
Kleiner Perkins
Versant Ventures

Global footprint

Where Five Prime Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown

Patent intelligence

$115M patent portfolio · 54 active families

Estimated portfolio value
$115M
6.0% of market cap · 17.7× smaller than top peer Ablynx ($2B)
54 active patent families
Where Five Prime Therapeutics innovates Molecular biologyPolynucleotideCancer researchCarcinosisAntiendomysial antibodies

Where Five Prime Therapeutics concentrates vs peers

Each axis is a top-10 topic across Five Prime Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Five Prime Therapeutics

An AI-synthesized read of the highest-engagement posts about Five Prime Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Five Prime Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.